We have recently designed and synthesized a novel iminoquinone anticancer agent, 7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1 H)-one (FBA-TPQ) and initiated its preclinical development. Herein we investigated its efficacy, safety, and pharmacokinetics in in vitro and in vivo models of human pancreatic cancer. Our results demonstrated that FBA-TPQ inhibited pancreatic cancer cell growth, induced apoptosis, and caused cell cycle arrest in vitro. It inhibited the growth of xenograft tumors with minimal host toxicity. To facilitate future preclinical and clinical development of the agent, we also developed and validated a Rapid Resolution Liquid Chromatography (RRLC) method for quantitative analysis of FBA-TPQ in plasma and tissue samples. The method was found to be precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of FBA-TPQ, including stability in plasma, plasma protein binding, metabolism by S9 enzymes, plasma pharmacokinetics, and tissue distribution. Our results indicate that FBA-TPQ is a potential therapeutic agent for pancreatic cancer, providing a basis for future preclinical and clinical development.
References
[1]
Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212–236, doi:10.3322/caac.20121.
[2]
Asuthkar, S.; Rao, J.S.; Gondi, C.S. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin. Investig. Drugs 2012, 21, 143–152, doi:10.1517/13543784.2012.651124.
Byler, K.; Wang, C.; Setzer, W. Quinoline alkaloids as intercalative topoisomerase inhibitors. J. Mol. Model. 2009, 15, 1417–1426, doi:10.1007/s00894-009-0501-6.
[5]
Guzmán, E.; Johnson, J.; Carrier, M.; Meyer, C.; Pitts, T.; Gunasekera, S.; Wright, A. Selective cytotoxic activity of the marine-derived batzelline compounds against pancreatic cancer cell lines. Anticancer Drugs 2009, 20, 149–155, doi:10.1097/CAD.0b013e32831fa39e.
[6]
Hoang, H.; LaBarbera, D.; Mohammed, K.; Ireland, C.; Skibo, E. Synthesis and biological evaluation of imidazoquinoxalinones, imidazole analogues of pyrroloiminoquinone marine natural products. J. Med. Chem. 2007, 50, 4561–4571, doi:10.1021/jm0700870.
[7]
Delfourne, E. Analogues of marine pyrroloiminoquinone alkaloids: Synthesis and antitumor properties. Anticancer Agents Med. Chem. 2008, 8, 910–916, doi:10.2174/187152008786847710. 19075573
[8]
Barrows, L.R.; Radisky, D.C.; Copp, B.R.; Swaffar, D.S.; Kramer, R.A.; Warters, R.L.; Ireland, C.M. Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors. Anticancer Drug Des. 1993, 8, 333–347. 8251041
[9]
Geldof, A.A.; Mastbergen, S.C.; Henrar, R.E.; Faircloth, G.T. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother. Pharmacol. 1999, 4, 312–318.
[10]
Mayer, A.M.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 2010, 31, 255–265, doi:10.1016/j.tips.2010.02.005.
[11]
Shinkre, B.A.; Raisch, K.P.; Fan, L.; Velu, S.E. Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines. Bioorg. Med. Chem. 2008, 16, 2541–2549, doi:10.1016/j.bmc.2007.11.051.
[12]
Shinkre, B.A.; Raisch, K.P.; Fan, L.; Velu, S.E. Analogs of the marine alkaloid makaluvamines: Synthesis, topoisomerase II inhibition, and anticancer activity. Bioorg. Med. Chem. Lett. 2007, 17, 2890–2893, doi:10.1016/j.bmcl.2007.02.065.
[13]
Wang, F.; Ezell, S.J.; Zhang, Y.; Wang, W.; Rayburn, E.R.; Nadkarni, D.H.; Murugesan, S.; Velu, S.E.; Zhang, R. FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest. New Drugs 2010, 28, 234–241, doi:10.1007/s10637-009-9232-x.
[14]
Wang, W.; Rayburn, E.R.; Velu, S.E.; Nadkarni, D.H.; Murugesan, S.; Zhang, R. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin. Cancer Res. 2009, 15, 3511–3518, doi:10.1158/1078-0432.CCR-08-2689. 19451594
[15]
Chen, T.; Xu, Y.; Guo, H.; Liu, Y.L.; Hu, P.T.; Yang, X.Y.; Li, X.G.; Ge, H.L.; Velu, S.E.; Nadkarni, D.H.; et al. Experimental therapy of ovarian cancer with synthetic makaluvamine analog: In vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One 2011, 6.
[16]
Wang, W.; Rayburn, E.R.; Zhao, Y.Q.; Wang, H.; Zhang, R.W. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: Anticancer activity and mechanisms of action. Cancer Lett. 2009, 18, 241–248.
[17]
Wang, W.; Zhao, Y.Q.; Rayburn, E.R.; Hill, D.L.; Wang, H.; Zhang, R.W. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother. Pharmacol. 2007, 59, 589–601, doi:10.1007/s00280-006-0300-z.
[18]
Wang, W.; Rayburn, E.R.; Hang, J.; Zhao, Y.Q.; Wang, H.; Zhang, R.W. Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 2009, 65, 306–311, doi:10.1016/j.lungcan.2008.11.016.
[19]
Wang, H.; Cai, Q.; Zeng, X.; Yu, D.; Agrawal, S.; Zhang, R.W. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 1999, 96, 13989–13994, doi:10.1073/pnas.96.24.13989. 10570186
[20]
Wang, W.; Rayburn, E.R.; Hao, M.; Zhao, Y.Q.; Hill, D.L.; Zhang, R.W.; Wang, H. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 2008, 68, 809–819, doi:10.1002/pros.20742.
[21]
Wang, W.; Wang, H.; Rayburn, E.R.; Zhao, Y.Q.; Hill, D.L.; Zhang, R.W. 20(S)-25-methoxyl-dammarane-3β,12β,20-triol, a novel natural product for prostate cancer therapy: Activity in vitro and in vivo and mechanisms of action. Br. J. Cancer 2008, 26, 792–802.
[22]
Li, H.B.; Ezell, S.J.; Zhang, X.R.; Wang, W.; Xu, H.X.; Rayburn, E.R.; Zhang, X.; Gurpinar, E.; Yang, X.Y.; Sommers, C.I.; et al. Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice. Biomed. Chromatogr. 2011, 25, 628–634, doi:10.1002/bmc.1498.
[23]
Ezell, S.J.; Li, H.B.; Xu, H.X.; Zhang, X.R.; Gurpinar, E.; Zhang, X.; Rayburn, E.R.; Sommers, C.I.; Yang, X.Y.; Velu, S.E.; et al. Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Mar. Drugs 2010, 13, 2129–2141.
[24]
Center for Drug Evaluation and Research (FDA). Guidance for Industry: Bioanalytical Methods Validation. U.S. Department of Health and Human Services Food and Drug Administration: Rockville, MD, USA, 2001. Available online: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed on 15 December 2009).
[25]
Prakash, C.; Vaz, A.D.N. Drug Metabolism: Significance and Challenges. In Nuclear Receptors in Drug Metabolism; Xie, W., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2009; pp. 1–42.
